

Alpha Seth to join Seattle Genetics' Board of Directors

16 March 2018 | News

She currently serves as Chief Operating Officer of Vir Biotechnology



Seattle Genetics, Inc. announced that Alpha Seth has been appointed to the company's Board of Directors. Dr. Seth has more than 20 years of global experience in the healthcare and biotechnology/pharmaceutical industry, including senior leadership positions at Biogen.

She currently serves as Chief Operating Officer of Vir Biotechnology, a San Francisco-based biotechnology company focused on transforming the care of people with serious infectious diseases.

Prior to joining Vir in July 2017, Dr. Seth was Senior Vice President and Global Head of the Biosimilars business for Biogen, Inc. since 2014. From 1998 through 2014, she held a range of leadership roles at Biogen in market and business development, drug development and commercial, including founding Managing Director of Biogen Idec India and Program Executive for several of Biogen's major cross-functional drug development programs and product launches.

She holds a Ph.D. in Biochemistry and Molecular Biology from University of Massachusetts Medical School and conducted her post-doctoral research at Harvard University in Immunology and Structural Biology, both as a Howard Hughes Medical Institute Fellow. She is also a 2002 graduate of the Advanced Management Program at Harvard Business School.